azithromycin - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.98 [0.89, 1.08]< 10%2 studies (2/-)65.3 %some concernnot evaluable moderatecrucial-
deaths 0.97 [0.88, 1.08]< 10%5 studies (5/-)69.5 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.98 [0.89, 1.08]< 10%2 studies (2/-)65.3 %some concernnot evaluable moderatecrucial-
clinical improvement 0.92 [0.70, 1.21]> 153%3 studies (3/-)28.2 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 0.76 [0.56, 1.04]> 10%2 studies (2/-)4.2 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 0.70 [0.47, 1.04]> 10%1 study (1/-)3.9 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.92 [0.69, 1.22]> 10%2 studies (2/-)27.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.08 [0.95, 1.23]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.95 [0.87, 1.03]< 10%1 study (1/-)88.3 %some concernnot evaluable moderateimportant-
hospital discharge 1.04 [0.98, 1.10]> 10%1 study (1/-)90.8 %some concernnot evaluable moderateimportant-
hospitalization 0.94 [0.50, 1.75]< 10%1 study (1/-)57.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.95 [0.68, 1.34]< 114%4 studies (4/-)61.3 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.64 [0.94, 2.88]> 10%1 study (1/-)95.8 %some concernnot evaluable moderateimportant-
ICU admission 0.47 [0.16, 1.37]< 10%2 studies (2/-)91.7 %some concernnot evaluable moderatenon important-

safety endpoints 00

related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %some concernnot evaluable moderateimportant-
serious adverse events 1.19 [0.82, 1.73]< 10%2 studies (2/-)17.8 %some concernnot evaluable moderateimportant-
adverse events 1.21 [0.82, 1.78]< 10%1 study (1/-)17.4 %some concernnot evaluable moderatenon important-
arrhythmia 0.90 [0.71, 1.14]< 10%2 studies (2/-)80.3 %some concernnot evaluable moderatenon important-
long QT 0.90 [0.56, 1.43]< 10%1 study (1/-)67.1 %some concernnot evaluable moderatenon important-
renal impairment 1.43 [1.00, 2.05]< 10%2 studies (2/-)2.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.